Castle Biosciences, Inc. (CSTL)
Stock Price:
$49.71 USD
-0.26 (-0.52%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
978.40M |
| Revenue (ttm) |
62.54M |
| Net Income (ttm) |
7.10M |
| Shares Out |
19.68M |
| EPS (ttm) |
-0.21 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 19, 2020 |
| Last Price |
$49.71 |
| Previous Close |
$49.97 |
| Change ($) |
-0.26 |
| Change (%) |
-0.52% |
| Day's Open |
50.10 |
| Day's Range |
49.44 - 50.37 |
| Day's Volume |
83,992 |
| 52-Week Range |
15.26 - 55.31 |
More Stats
| Market Cap |
978.40M |
| Enterprise Value |
823.38M |
| Earnings Date (est) |
Nov 16, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
19.68M |
| Float |
13.76M |
| EPS (basic) |
0.56 |
| EPS (diluted) |
-0.21 |
| FCF / Share |
0.90 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
1.61% |
| Payout Ratio |
n/a |
| Shares Short |
733,752 |
| Short Ratio |
3.29 |
| Short % of Float |
5.33% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
62.21 |
| PS Ratio |
15.64 |
| PB Ratio |
6.59 |
| Revenue |
62.54M |
| Operating Income |
7.43M |
| Net Income |
7.10M |
| Free Cash Flow |
15.73M |
| Net Cash |
155.02M |
| Net Cash / Share |
7.88 |
| Gross Margin |
71.24% |
| Operating Margin |
11.88% |
| Profit Margin |
10.90% |
| FCF Margin |
25.14% |
| ROA |
2.95% |
| ROE |
9.22% |
| ROIC |
36.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$55.00*
(10.64% upside)
Low
50.0
Current: $49.71
High
61.0
Target: 55.00
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 51.87 | 22.79 | 13.75 |
| Revenue Growth | 127.62% | 65.67% | - |
| Gross Profit | 44.56 | 17.49 | 8.83 |
| Operating Income | 7.33 | -3.84 | -10.90 |
| Net Income | 5.28 | -6.37 | -12.37 |
| Shares Outstanding | 8.58 | 1.91 | 1.90 |
| Earnings Per Share | -0.21 | -5.33 | -8.08 |
| Operating Cash Flow | 7.02 | -12.30 | -12.23 |
| Capital Expenditures | -0.94 | -0.28 | -0.49 |
| Free Cash Flow | 6.08 | -12.57 | -12.73 |
| Cash & Equivalents | 98.85 | 4.48 | 1.21 |
| Total Debt | 25.12 | 24.50 | 18.60 |
| Net Cash / Debt | 73.72 | -20.02 | -17.39 |
| Assets | 120 | 22.41 | 9.82 |
| Liabilities | 34.63 | 32.48 | 24.09 |
| Book Value | 85.11 | -56.57 | -50.31 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Castle Biosciences, Inc. |
| Country |
United States |
| Employees |
133 |
| CEO |
Derek J. Maetzold |
Stock Information
| Ticker Symbol |
CSTL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: CSTL |
| IPO Date |
July 25, 2019 |
Description
Castle Biosciences, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.